Kane Biotech’s Revyve™ Wound Gel Gains Health Canada Approval

Kane Biotech Inc. announced today that it has gained approval from Health Canada for its revyve™ Antimicrobial Wound Gel, now classified as a Class 2 medical device. With this approval, the company can begin promoting and selling the product across Canada immediately.

“We are excited to bring this much-needed product to Canada. Congratulations to the Kane Biotech team for achieving this important milestone and continuing to execute our strategic plan,”  said Marc Edwards, President & CEO.